Cargando…

Development and validation of a prognostic model for esophageal carcinoma based on immune microenvironment using system bioinformatics

Esophageal cancer (EC) is an aggressive malignancy that accounts for numerous cancer‐related deaths worldwide. The multimodal combination therapy approach can be potentially used to treat EC effectively. However, distinct biomarker of significant specificity are still needed to develop individualize...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Chenchun, Feng, Shicheng, Wang, Sheng, Su, Xiangyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883539/
https://www.ncbi.nlm.nih.gov/pubmed/35771026
http://dx.doi.org/10.1002/cam4.4985
_version_ 1784879530874241024
author Fu, Chenchun
Feng, Shicheng
Wang, Sheng
Su, Xiangyu
author_facet Fu, Chenchun
Feng, Shicheng
Wang, Sheng
Su, Xiangyu
author_sort Fu, Chenchun
collection PubMed
description Esophageal cancer (EC) is an aggressive malignancy that accounts for numerous cancer‐related deaths worldwide. The multimodal combination therapy approach can be potentially used to treat EC effectively. However, distinct biomarker of significant specificity are still needed to develop individualized treatment strategies and provide accurate prognostic predictions. Therefore, we aimed to investigate the associated genes subtypes identified were, IFN‐γDominant, Inflammatory, Lymphocyte Depleted, etc. and construct a risk model based on these genes to predict the overall survival (OS) of patients suffering from EC. Three immune subtypes were defined in the Cancer Genome Atlas (TCGA) cohort with different tumor microenvironment (TME) and clinical outcomes based on radio‐differentiated immune genes. Subsequently, a risk model of immune characteristics included the immune cell infiltration levels and pathway activity was developed based on the genomic changes between the subtypes. In the TCGA dataset, as well as in subgroup analysis with different stages, gender, age, and pathological type, a high‐risk score was identified as an adverse factor for OS using the method of the univariate Cox regression analysis and tROC analysis. Furthermore, it was observed that the high‐risk group was characterized by depleted immunophenotype, active cell metabolism, and a high tumor mutation burden (TMB). The low‐risk group was characterized by high TME abundance and active immune function. Differences in the biological genotypes may account for the differences in the prognosis and treatment response. Extensive research was carried out, and the results revealed that the low‐risk group exhibited a significant level of therapeutic advantage in the field of immunotherapy. A risk model was developed based on the immune characteristics. It can be used to optimize risk stratification for patients suffering from EC. The results can potentially help provide new perspectives on treatment methods.
format Online
Article
Text
id pubmed-9883539
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-98835392023-01-31 Development and validation of a prognostic model for esophageal carcinoma based on immune microenvironment using system bioinformatics Fu, Chenchun Feng, Shicheng Wang, Sheng Su, Xiangyu Cancer Med Research Articles Esophageal cancer (EC) is an aggressive malignancy that accounts for numerous cancer‐related deaths worldwide. The multimodal combination therapy approach can be potentially used to treat EC effectively. However, distinct biomarker of significant specificity are still needed to develop individualized treatment strategies and provide accurate prognostic predictions. Therefore, we aimed to investigate the associated genes subtypes identified were, IFN‐γDominant, Inflammatory, Lymphocyte Depleted, etc. and construct a risk model based on these genes to predict the overall survival (OS) of patients suffering from EC. Three immune subtypes were defined in the Cancer Genome Atlas (TCGA) cohort with different tumor microenvironment (TME) and clinical outcomes based on radio‐differentiated immune genes. Subsequently, a risk model of immune characteristics included the immune cell infiltration levels and pathway activity was developed based on the genomic changes between the subtypes. In the TCGA dataset, as well as in subgroup analysis with different stages, gender, age, and pathological type, a high‐risk score was identified as an adverse factor for OS using the method of the univariate Cox regression analysis and tROC analysis. Furthermore, it was observed that the high‐risk group was characterized by depleted immunophenotype, active cell metabolism, and a high tumor mutation burden (TMB). The low‐risk group was characterized by high TME abundance and active immune function. Differences in the biological genotypes may account for the differences in the prognosis and treatment response. Extensive research was carried out, and the results revealed that the low‐risk group exhibited a significant level of therapeutic advantage in the field of immunotherapy. A risk model was developed based on the immune characteristics. It can be used to optimize risk stratification for patients suffering from EC. The results can potentially help provide new perspectives on treatment methods. John Wiley and Sons Inc. 2022-06-30 /pmc/articles/PMC9883539/ /pubmed/35771026 http://dx.doi.org/10.1002/cam4.4985 Text en © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Fu, Chenchun
Feng, Shicheng
Wang, Sheng
Su, Xiangyu
Development and validation of a prognostic model for esophageal carcinoma based on immune microenvironment using system bioinformatics
title Development and validation of a prognostic model for esophageal carcinoma based on immune microenvironment using system bioinformatics
title_full Development and validation of a prognostic model for esophageal carcinoma based on immune microenvironment using system bioinformatics
title_fullStr Development and validation of a prognostic model for esophageal carcinoma based on immune microenvironment using system bioinformatics
title_full_unstemmed Development and validation of a prognostic model for esophageal carcinoma based on immune microenvironment using system bioinformatics
title_short Development and validation of a prognostic model for esophageal carcinoma based on immune microenvironment using system bioinformatics
title_sort development and validation of a prognostic model for esophageal carcinoma based on immune microenvironment using system bioinformatics
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883539/
https://www.ncbi.nlm.nih.gov/pubmed/35771026
http://dx.doi.org/10.1002/cam4.4985
work_keys_str_mv AT fuchenchun developmentandvalidationofaprognosticmodelforesophagealcarcinomabasedonimmunemicroenvironmentusingsystembioinformatics
AT fengshicheng developmentandvalidationofaprognosticmodelforesophagealcarcinomabasedonimmunemicroenvironmentusingsystembioinformatics
AT wangsheng developmentandvalidationofaprognosticmodelforesophagealcarcinomabasedonimmunemicroenvironmentusingsystembioinformatics
AT suxiangyu developmentandvalidationofaprognosticmodelforesophagealcarcinomabasedonimmunemicroenvironmentusingsystembioinformatics